David Debruyn Email & Phone Number

Benelux

Independent consultancy to broaden scope beyond pharmaceuticals-involved in government forming and the 7 year plan for social security both on federal level (Social Security, Sick funds, Verzekeringscomité)-outlaying all the plans for the Flemish region, amounting up to 1.1B€ in non-medical care. The biggest investment up to date in mental wellbeing.

Benelux

Responsible for optimizing access for the full company portfolio:- defending / renegotiating in line products approaching LoE such as blockbusters Xospata (AML), Evrenzo (CKD) and Xtandi (Pr. C). -while leading the pre launch teams to prepare the launches for exciting new compounds such as Padcev, Vyloy, and fenolinezetant.

Brussels Region, Belgium

• Development of both pricing and reimbursement files (Class I, Class II, art.59) in (hemato-)oncology, orphan and respiratory
• Procedure follow up: responding to payer evaluation reports (FOD Economy, Day 60, 120, Day 150, MEA agreements)
• Day-to-day responsibilities: project management with external vendors (medical writer, local adaptation of BIMs and C-E models), internal collaboration to develop the reimbursement strategy, co-create dossiers and.

Belgium

• Responsible for the Myeloid portfolio (>50% future revenues)
• Manages 2 out of 5 in-market assets (forecasting, creation of new materials for field force, lifecycle management strategies, LoE defense)
• Project management of 20 transversal projects aimed at supporting haematologists, pharmacists, nurses and patients
• Overall responsibilities: Disease plan building and implementing the tactics, pre-launch, forecasting, OpEx planning, organising local congresses and AdBoards, insights gathering with KOLs, market research, creation of.

Amsterdam, Germany, Israel. Belgium

• Elite taskforce (2 / 1400 accepted Europe-wide) with 4 assignments across different businesses and locations: European Pricing & Market Access - EU HQ Amsterdam
• European tender strategy and biosimilar defences with different gross-to-net implications for a 5B$ blockbuster reaching LoE
• Development of pricing strategy and launch sequence for new products & price erosion analyses (International Price Referencing)
• Monitoring supply chain integrity, development of payer deliverables for local markets Gx Portfolio Value Optimisation - Ulm, Germany
• Tail Portfolio streamlining reducing low profitability SKUs => RA savings, operational cost reductions (impact: ~15% of global volume)
• Initiated operational improvements on top 50 Gx products: manufacturing footprint optimisation such as site harmonisations, divestitures, cheaper API sourcing, dual sourcing, make vs. buy considerations, and other BD.

Europe

1) vendor due diligence of a PE-owned anti-biotics production sites2) top line growth programme and portfolio rationalisation for a top 5 FMCG leader.

London Area, United Kingdom

Traditional investment banking internship: assisted on a carve out of a 50B+ revenue generating listed company.